۲ Small Biotechs With Substantial Upside Potential
The biotech sector is perking up this week on the back of two big acquisitions and improved sentiment on the space.
Increased M&A activity is something that should be in the cards for 2018 and will be a tailwind for the sector.
In today’s piece on the biotech space we look at two promising biotech stocks we like and that analysts currently believe could go much higher.
No guilt is forgotten so long as the conscience still knows of it.” ― Stefan Zweig
Today, we look at two small promising biotechs that we like and own. Both companies also enjoy widespread positive sentiment in the analyst community who believe the stocks could move substantially higher on upcoming catalysts.
Let’s start with a small ‘Tier 4‘ biotech concern that has a lot of promise. In fact, based on the current median analyst price target, the shares seem to have the potential to more than triple should things fall the company’s way over the next year or two.
Syndax Pharmaceuticals (SNDX) is a Massachusetts-based biotech concern focused on developing and progressing its promising pipeline of combination therapies in several oncology indications. Syndax came public early in 2016 and currently carries a market capitalization of just under $250 million. The shares currently trade at approximately $11.00 a share.
The company’s lead clinical candidate ‘entinostat’ is a Class 1, selective HDAC inhibitor which has been shown to block myeloid-derived suppressor cells and regulatory T-cells. Convenient dosing is an interesting differentiator (once-weekly oral) as is the fact that so far the drug has been well tolerated in combination with other treatments. Preclinical data has demonstrated signs of efficacy when combined with anti-PD-1 treatments.